Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.41 |
| ▸ | TRPC7 | Q9HCX4 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.40 |
| ▸ | BCL9 | O00512 | 3/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901233 | 0.91 | JAK2 (0.46) | JAK2JAK1TYK2JAK3USP30 | |
| SCHEMBL13901487 | 0.90 | TRPC3 (0.49) | JAK2JAK1TYK2JAK3USP30 | |
| SCHEMBL13901347 | 0.90 | JAK2 (0.44) | JAK2JAK1TYK2JAK3USP30 | |
| SCHEMBL13305009 | 0.90 | USP30 (0.45) | JAK2JAK1TYK2JAK3USP30 | |
| SCHEMBL13305223 | 0.90 | TRPC3 (0.44) | JAK2JAK1TYK2JAK3USP30 | |
| SCHEMBL12953255 | 0.90 | CHEK1 (0.48) | JAK2JAK1TYK2JAK3USP30 | |
| SCHEMBL14050909 | 0.86 | CHEK1 (0.42) | JAK2JAK1TYK2JAK3USP30 | |
| SCHEMBL11931160 | 0.81 | USP30 (0.45) | JAK2JAK1TYK2JAK3USP30 | |
| SCHEMBL13901218 | 0.81 | TRPC3 (0.53) | JAK2JAK1TYK2JAK3USP30 | |
| SCHEMBL11931178 | 0.80 | JAK2 (0.42) | JAK2JAK1TYK2JAK3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511049-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511049-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7309705-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309705-B2 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070275983-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070275983-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION | 2007-11-29 | — | — | US | disclosed |
| EP-1534710-B1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275983-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CDKN1A | JAK2 303/4885JAK1 179/4885TYK2 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.